UK

Downing Street, London, UK
#BioIndustry Association #Life sciences #UK #UK government

UK government commits £1.5bn to life sciences  

The UK government has pledged £1.5 billion ($2.1 billion) for R&D in life sciences over the next four years.  Speaking at the BioIndustry Association (BIA)’s Gala Dinner, Liz Kendall, the Secretary of State for Science, Innovation and Technology, confirmed the funding for life sciences as part of the government’s… Read More

#News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

Drug manufacturing
#Gedeon Richter #Neuropsychiatric disorders #Recordati #UK

Gedeon Richter UK announces transfer of neuropsychiatry product 

Pharmaceutical company Gedeon Richter UK has received full marketing and distribution rights for neuropsychiatry treatment Reagila (cariprazine).  Reagila was acquired by Gedeon Richter UK from Recordati Pharmaceuticals, with Gedeon Richter picking up the rights for UK promotion of cariprazine. The drug is currently licensed in the UK… Read More

#Business & Investment #News

Lab of the future
#Cancer #The University of Manchester #UK

New UK lab to accelerate cancer diagnostic solutions 

A new state-of-the-art lab has opened in the UK to accelerate the development of cancer diagnostic solutions.  Vortex Biotech has opened a new laboratory at Manchester Science Park, hoping to accelerate the development of cancer diagnostic solutions. The laboratories are designed to GLP-ready specifications, allowing future expansion into clinical trial support and commercial product… Read More

#Cancer Research #News

UK
#Biotech #Europe #UK #UK government

UK is Europe’s leading biotech market, BIA report shows 

The UK retained its position as Europe’s leading national biotech market in 2025, a new report finds.   The BioIndustry Association’s (BIA) report ‘UK biotech financing 2025’ shows the UK market claimed 30% of all European venture financing.  That comes despite a 13.2% year–on–year drop in venture capital… Read More

#Business & Investment #News

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

DDW Highlights: 27 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

#Podcasts

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

This week in Drug Discovery (19 – 23 January) 

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.  The top stories:    Combination therapy could slash melanoma mortality… Read More

#News

Conference microphone
#Cell and gene therapy #ELRIG #UK

ELRIG announces keynote speakers for CGT conference 

ELRIG has announced Dr Stephen Ward and Dr Annarita Miccio as keynote speakers for its Cell and Gene Therapy event in March.  The not-for-profit organisation aims to bring together leading scientists, economists and patient advocates to explore breakthroughs shaping the future of medicine.   The programme, focussing on… Read More

#News

#GlobalData #Investment #Pharmaceutical industry #Politics #Tariffs #UK #United States

Is US foreign policy uncertainty strengthening confidence in the UK?

The recent UK-US policy developments are reshaping global pharmaceutical investment and launch strategies, according to intelligence platform GlobalData.  In December 2025, the UK announced a landmark pharmaceuticals agreement with the US, granting UK-made medicines and medical technologies tariff-free access to the US market for… Read More

#Business & Investment #News #Trending News

Clinical trial
#Canada #UK #Vaccines

UK-Canadian partnership to advance vaccine technology 

A £750,000 ($1 million) global collaboration has been launched to advance next-generation vaccine technology.  iiDiagnostics (iiDX), a company formed by the Infection Innovation Consortium: iiCON, and Canadian biotech Eyam Health have launched a collaboration to bring forward Eyam Health’s novel vaccine technology using advanced automated organoid models.   This £750,000… Read More

#Business & Investment #News

Innovation Centre, London
#Medical Research Council #National Institute for Health Research #UK

New £50 million MRC Centre to transform clinical trials 

A new £50 million ($67 million) Medical Research Council Centre is set to overhaul clinical trials for UK patients.  The Medical Research Council Centre of Research Excellence in Clinical Trial Innovation, in partnership with the National Institute for Health and Care Research, will receive up to £50 million ($67 million) over… Read More

#News

Great British Pounds, Investment
#ABPI #Drug discovery #UK #UK economy

UK payment rate for new medicines drops to 14.5% in 2026  

The 2026 payment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) will be 14.5%, down from a record 22.5% in 2025, the UK government has announced.   This news follows the recent announcement of the UK-US trade agreement… Read More

#News

Scientist in laboratory
#BioIndustry Association #Rare diseases #UK

Reform needed to give patients rare disease medicines 

The BioIndustry Association (BIA) has called for a new, reformed pathway to give UK patients access to innovative rare disease medicines.   According to the BIA’s new report, while the UK’s rare disease ecosystem has a solid foundation, more work is needed to build a connected, flexible and risk-proportionate access pathway to… Read More

#News

Subcutaneous injection
#ABPI #Clinical trial #UK #UK government

Decline in trial recruitment denying patients, ABPI warns 

The decline in commercial clinical trial recruitment is denying patients participation in cutting-edge research, the Association of the British Pharmaceutical Industry (ABPI) has warned.  According to the ABPI’s annual clinical trials report, the number of patients recruited into UK industry clinical trials fell by 25% between 2022/23… Read More

#News

#Education #STEM #UK

Horiba initiative to widen UK scientific participation 

Global manufacturer Horiba UK has announced the launch of the Horiba Foundation UK, a new initiative to advance scientific research and broaden STEM participation. The Horiba Foundation UK will work with universities and their established mechanisms through a range of initiatives, including grants, scholarships,… Read More

#News